Category: Press Releases

Solution integrates controls capture directly into Financial Close and other processes, reducing complexity, costs, and compliance implementation and maintenance efforts

LOS ANGELES, May 23, 2023 (GLOBE NEWSWIRE) — Today, FloQast, a provider of accounting workflow automation software created by accountants for accountants, announced the launch of FloQastCompliance Management, an advanced workflow solution that helps finance, accounting, and internal audit teams centrally manage and integrate compliance into business processes for continuous audit readiness and integrity. Offered as part of FloQast’s cloud-native Accounting Operations Platform, FloQast Compliance Management integrates with FloQastClose Management and FloQast Ops to deliver the ability to set up controls capture directly into the Financial Close and other business operations like payroll processing and financial reporting. Now, organizations can monitor controls in real-time and align around their compliance program, reducing risk and giving control owners clear visibility into ownership and accountability.

FloQast Compliance Management reduces the cost and effort of implementing and maintaining new compliance and controls programs. Organizations can streamline end-to-end compliance management, reducing manual effort and gaining the scalability and agility to meet changing business environments and compliance regulations. FloQast Compliance Management complements additional, existing compliance-related solutions and coexists seamlessly with the tools control managers rely on to manage their compliance program, including spreadsheets, cloud storage, email, and messaging platforms.

“Internal compliance teams are under huge amounts of pressure to deliver more detailed information to external auditors and organizational leadership, but too often rely on disconnected solutions and manual processes to manage compliance programs,” said Mike Whitmire, CEO and co-founder of FloQast, CPA. “FloQast Compliance Management automates these manual efforts for a more data-driven, collaborative audit that better empowers organizations to respond to changing regulatory and business environments and foster happier teams.”

The burden of compliance on organizations has never been greater. Between a complex and ever-evolving regulatory environment, staffing shortages, and rising compliance costs, many companies struggle with the visibility and coordination required to navigate the compliance landscape. In fact, recent research from FloQast indicated the average organization spends about $2.4 million annually on compliance and control processes, however only 26% of professionals feel their existing compliance and control management processes add significant value to the organization.

According to Michael Rasmussen, GRC 2020 Pundit and Analyst, “There will only be more regulatory requirements, complexity and costs to maintain GRC programs on the horizon. To more effectively manage this reality companies will need to adopt GRC 6.0 – Business Integrated GRC, which integrates risk, compliance and controls management into core business processes, that will deliver greater visibility, assurance, and efficiency across all their compliance efforts.”

FloQast Compliance Management optimizes organizations’ compliance and controls programs through:

• Continuous Controls Capture for Better Visibility and Accountability: With FloQast Compliance Management, teams capture financial controls while performing daily tasks like the Close or account reconciliation for clear visibility into control ownership, responsibilities, and execution. Teams can enforce control testing and shift accountability back to business task owners.
• Synchronized Risk Control Matrix (RCM), Process Narratives, and Flowcharts: FloQast Compliance Management automatically synchronizes teams’ Risk Control Matrix (RCM) to process narratives and flowcharts for real-time capture and storage of audit evidence that is always current and in sync, reducing the time and effort needed to prepare for audit by both accountants and auditors.
• PBC Automation for Simplified Collaboration: FloQast Compliance Management automates Prepared By Client (PBC) processes for easier collaboration between Finance, Accounting, and Audit by capturing audit evidence during financial control execution and synchronizing it to teams’ RCM. Internal and external auditors can now work in parallel off a single source of audit truth, eliminating duplicate audit activities and complexity by reducing the number of requests for information and clarifications. The Audit becomes more efficient with reduced audit cycle times and cleaner audit data that is easier to access and share
• Embedded Testing for Audit Efficiency: Internal auditors can now track control owners’ assignments while defining and executing their testing plans in the system, eliminating the need for a separate testing platform. With intuitive dashboards, auditors and financial control owners have real-time visibility into the progress of both controls and testing with easy drill-downs back to each business process. Finance, Accounting, and Audit can work as a unified team to find and address control design gaps for continuous optimization and total compliance assurance.

Brandon Peters, Director of SOX Compliance & Head of Internal Audit, a.k.a Brands said, “With FloQast Compliance Management, we have centralized our compliance program for one source of truth and linked controls to checklist items, capturing evidence during financial close task execution and increasing accountability and visibility among control owners.”

For more information on FloQast Compliance Management:

• Visit the website
• Read the blog post
• Watch a video overview

About FloQast
FloQast, a provider of accounting workflow automation software created by accountants for accountants, delivers an Accounting Operations Platform that enables organizations to operationalize accounting excellence. Trusted by more than 2,200 accounting teams – including Twilio, Los Angeles Lakers, Zoom, and Snowflake – FloQast was built by accountants, for accountants to enhance the way accounting teams work. FloQast enables customers to streamline and manage the Financial Close, Finance and Accounting Operations, and Compliance Programs. With FloQast, teams can manage every aspect of the month-end Close, reduce their compliance burden, stay audit-ready, and improve accuracy, visibility, and collaboration throughout the financial function. FloQast is consistently rated #1 across all user review sites. Learn more at FloQast.com.

Contact:
Kyle Cabodi
FloQast Director of Corporate Communications
kyle.cabodi@floqast.com

GlobeNewswire Distribution ID 8844177

Strong customer tailwinds continue to push Builder.ai’s vision of empowering everyone to build the software they need for their business or ideas and making it as easy as ordering pizza

LONDON and DOHA, Qatar, May 23, 2023 (GLOBE NEWSWIRE) — Builder.ai®, the AI powered composable software platform, designed to be so simple and accessible that everyday businesses and individuals can turn their ideas into software, today announced an investment of over $250 million in Series D funding. The new investment, led by Qatar Investment Authority (QIA) takes the total amount raised by the company to over $450 million with an up to 1.8x increase in its valuation.

The latest round of capital will fuel the company’s continued industry leadership and innovation pipeline allowing further investments in talent, partnerships, and technology; with a bigger focus on using human conversation as the primary user interface for allowing people to build software rather than the expert-laden white-canvas systems we are used to seeing in the no-code/low-code space. With customer demand at an all-time high, and AI advancing every day, the company has almost doubled its headcount since January 2022, and extended its UK HQ footprint with four new offices opened since 2021 – including the USA, the UAE, Singapore, and France.

Continued investor support – combined with strategic partnerships, customer tailwinds and acclaimed industry innovation – helped drive the company’s momentum with 2.3x revenue growth and over 40,000 features deployed to customers within the last year.

The Series D round included participation from additional existing and new investors including Iconiq Capital, Jungle Ventures & Insight Partners.

“Builder.ai was founded on the promise that everyone should be empowered to unlock their human potential. Today this means being able to build software to be able to do more with less. We are entering an incredible time in history where the very notion of software is changing; from something that had a shelf life of years to what will eventually have a shelf life of a conversation and the volume of what is being created is only going to grow exponentially,” said Sachin Dev Duggal, Chief Wizard and Founder of Builder.ai.

Duggal added “With the support of our investors and the dedication and drive of our team, we are further empowered to unlock our own potential. Our growth strategy has always been driven by a DNA based on being able to do more with less and this has weaved into our shared vision with our customers around the world as everyone pushes the envelope to do more. It is what attracted our first-round investors in 2018, and what drives this Series D today. Our team is already investing this capital in our AI and automation capabilities, not only keeping pace with the fast-moving industry, but leading from the front so we can empower our customers more and at the same time use new frontier technology responsibly.”

“QIA is very excited to be partnering with the leader in this space. We are confident that Builder.ai’s innovative technology and proven approach positions the company for a future of substantial growth. This investment is aligned with QIA’s strategy of supporting innovative companies shaping the future of the global economy,” said Ahmed Ali Al-Hammadi, CIO for Europe, Türkiye and Russia at QIA.

“Sachin and the Builder.ai team have produced tremendous results since Insight invested one year ago. We are thrilled to be doubling down on our support of the company,” Jeff Horing, Co-Founder and Managing Director at Insight Partners.

Established in 2016, Builder.ai continues to lead the industry with its AI-powered composable software platform that allows anyone with an idea to build an app (web or mobile) – faster and 70% more affordably. Breaking software down into its reusable lego-like features, coupled with customization from its managed expert network of designers and developers atop its human assisted AI powered assembly line, has been the key to Builder.ai’s performance and that of its customers’ successful digital transformations worldwide.

The brand has also furthered its partnership with Microsoft for a holistic global GTM and inclusion in their reseller program, as well as entered into partnerships with JP Morgan & Chase, Etisalat UAE and other technology and financial enterprises. These partnerships, along with the company’s visionary application of AI, have landed Builder.ai on the 2023 Fast Company list of Most Innovative Companies, won them the 2022 Europas “Scale Up of the Year”  and placed them firmly in the 2021 Gartner® Magic Quadrant for Multi Experience Development Platforms (MXDP) and MarketGuide 2022 for MXDP, as well as inclusion in the final round of consideration for 2022 Gartner® Magic Quadrant for low code application platforms (LCAP).

The transaction is subject to customary closing conditions.

Goodwin acted as legal advisor to Builder.ai.

About Builder.ai

Builder.ai® is an AI powered composable software platform for every idea and company on the planet. The AI-powered assembly line fuses together Lego-like reusable features, using Building Blocks automation to reduce human effort, leveraging a verified network of experts to vastly extend development capabilities, and producing apps at almost zero failure rate that are multitudes cheaper and faster than traditional software development.

Led by British Indian serial entrepreneur Sachin Dev Duggal, Builder.ai is reshaping how software is built and operated with a suite of products and services, including BUILDER STUDIO, BUILDER CLOUD, BUILDER NOW, STUDIO STORE and STUDIO RAPID. In 2020, Builder.ai was awarded ‘Hottest AI Startup’ and 2022’s “Hottest Scale-Up” at the Europas for Europe’s successful tech start-ups and Best COVID-19 Innovation-Recovery at CogX and awarded ‘Visionary’ in the 2021 Gartner® Magic Quadrant for Multi-experience Development Platforms. Builder.ai is headquartered in London, supported by employees and hubs in Delhi NCR, Singapore, Los Angeles, Salt Lake City, Sophia Antipolis and Dubai. For more information, visit Builder.ai.

BUILDER.AI and BUILDER are trademarks of Engineer.ai Corp. All other marks are trademarks of their respective owners.

About Qatar Investment Authority
Qatar Investment Authority (“QIA”) is the sovereign wealth fund of the State of Qatar. QIA was founded in 2005 to invest and manage the state reserve funds. QIA is among the largest and most active sovereign wealth funds globally. QIA invests across a wide range of asset classes and regions as well as in partnership with leading institutions around the world to build a global and diversified investment portfolio with a long-term perspective that can deliver sustainable returns and contribute to the prosperity of the State of Qatar.

Media Contact
Builder.ai
Stephanie Lowenthal
stephanie.lowenthal@builder.ai

Qatar Investment Authority
media@qia.qa

GlobeNewswire Distribution ID 1000821323

Jetex signs a milestone agreement with 360 Jet Fuel Ltd. to offer sustainable aviation fuel (SAF) book and claim option to its customers globally. Through the innovative 360 GREEN FUEL book and claim platform, Jetex aims to offer greater flexibility and accessibility to SAF.

Dubai, United Arab Emirates, May 23, 2023 (GLOBE NEWSWIRE) — Jetex entered in an agreement with 360 Jet Fuel Ltd. to offer its customers more flexibility and wider access to sustainable aviation fuel (SAF).

SAF is a liquid fuel currently used in commercial aviation which reduces CO2 emissions by up to 80%. It can be produced from a number of sources including waste oil and fats, green and municipal waste and non-food crops. It can also be produced synthetically via a process that captures carbon directly from the air.

Part of what makes SAF sustainable is ensuring sustainability in its supply chain. Transporting SAF to a specific airport or flight is not always possible and could lead to higher greenhouse gas emissions. The Book & Claim system provides a solution for these situations.

The new 360 GREEN FUEL book & claim system allows Jetex customers to source SAF based on their total aviation footprint in one transaction, rather than sourcing through each location individually. This means that SAF can be sourced for flights out of airports that do not have SAF supply available.

Sourcing SAF on a Book & Claim basis will allow purchasing any volume of SAF, including 100% of fuel needs or a carbon neutral scenario, without technical limitations such as blending limits.

Jetex customers will be able to claim the C02 emission reduction they achieved by the amount of fossil fuel replaced with SAF acquired They will receive a certificate specifying the amount of SAF purchased and an audited statement outlining the corresponding CO2 reduction. This documentation can be utilized for sustainability reporting purposes.

To ensure credibility and verifiable emission reductions, 360 Jet Fuel sources physical SAF quantities from ISCC+ certified suppliers, guaranteeing full traceability of the claimed amounts, and ensures delivery to an airline partner within the aviation sector. The solution provided by 360 Jet Fuel undergoes rigorous third-party auditing, ensuring traceability to each delivery batch and eliminating any doubts of double claiming.

The new agreement takes Jetex a step closer to being fully carbon-neutral globally and is aligned with IATA’s commitment to achieving 65% SAF share by 2050.

Click here to see Adel Mardini, Founder & CEO of Jetex, on progressing the sustainability agenda.

About Jetex:
An award-winning global leader in executive aviation, Jetex is recognized for delivering flexible, best-in-class trip support solutions to customers worldwide. Jetex provides exceptional private terminals (FBOs), aircraft fueling, ground handling and global trip planning. The company caters to both owners and operators of business jets for corporate, commercial and personal air travel. To find out more about Jetex, visit www.jetex.com and follow us on Instagram, Twitter, Facebook, and LinkedIn.

Attachment

• JETEX INTRODUCES SUSTAINABLE AVIATION FUEL BOOK & CLAIM

Oleg Kafarov - Director of Portfolio Development & Corporate Communications
Jetex
+971 4 212 4900
teamorange@jetex.com

GlobeNewswire Distribution ID 8844534

SHANGHAI, China, May 23, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (“NMPA”) has accepted the supplemental new drug application (“sNDA”) for the company’s anti-PD-1 monoclonal antibody, toripalimab, used in combination with albumin-bound paclitaxel for the treatment of PD-L1 positive (CPS ≥ 1) untreated metastatic or recurrent metastatic triple-negative breast cancer (“TNBC”).

According to GLOBOCAN 2020, breast cancer exhibited the highest incidence rates worldwide, with 2.26 million new cases and 0.68 million deaths in 2020. In China, 0.42 million new cases and 0.12 million deaths due to breast cancer were reported in 2020, accounting for 18.4% and 17.1% of global cases, respectively. Amongst these breast cancer cases, approximately 10% to 15% were classified as TNBC. TNBC is a more aggressive type of cancer with a higher risk of recurrence and a poor prognosis. Unfortunately, advanced TNBC does not respond well to targeted therapy and endocrine therapy, and there are currently no specific treatment methods available.

In recent years, clinical studies have shown that immunotherapy in combination with chemotherapy for the treatment of advanced TNBC can achieve better efficacy and tolerability. To this day, however, no immunotherapy drugs have been approved for advanced TNBC in China, and chemotherapy remains the primary treatment option. Alternative drugs include anthracyclines, taxanes, platinum-based drugs, etc. Both mono-chemotherapy and combination chemotherapy have poor efficacy, with a median survival time of about 9 to 12 months and a 5-year survival rate of less than 30%.

The supplemental new drug application is based on the TORCHLIGHT study (NCT04085276), which is a randomized, double-blind, placebo-controlled, multi-center Phase III clinical study jointly conducted across 56 centers nationwide, with Professor Zefei JIANG from the Department of Oncology of the Chinese People’s Liberation Army General Hospital and Vice President and Secretary General of the Chinese Society of Clinical Oncology (CSCO), serving as the principal investigator. The study was designed to compare the efficacy and safety of toripalimab combined with albumin-bound paclitaxel versus placebo combined with albumin-bound paclitaxel in patients with an initial diagnosis of stage IV or recurrent metastatic TNBC. In February 2023, the Independent Data Monitoring Committee (IDMC) determined in an interim analysis that the primary endpoint of the TORCHLIGHT study had met its pre-defined efficacy boundary.

TORCHLIGHT study is the first domestic Phase III registered study to achieve positive results in advanced TNBC immunotherapy. The study results showed that, compared with albumin-bound paclitaxel alone, toripalimab in combination with albumin-bound paclitaxel in patients with an initial diagnosis of stage IV or recurrent metastatic triple-negative breast cancer could significantly prolong the progression-free survival (“PFS”) of PD-L1 positive patients. Meanwhile, the overall survival (“OS”), one of the secondary endpoints, also showed a clear trend of improvement in PD-1 positive patients as well as in all patients, regardless of PD-1 status. The safety profile of toripalimab is consistent with known checkpoint inhibitor-related risks, and no new safety signals were identified.

Details of the TORCHLIGHT results will be published in the form of a “Late-breaking Abstract (LBA)” (#LBA1013) oral presentation during the rapid abstract session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

“Over 2 million breast cancer cases occur annually, making it the most prevalent cancer worldwide,” said Professor Zefei JIANG from the Department of Oncology of the Chinese People’s Liberation Army General Hospital. “While advancements in breast cancer treatment have continued to improve patient prognosis, TNBC remains a challenging subtype characterized by its aggressive nature and poor prognosis. Effective treatment methods for TNBC are still lacking, and the 5-year survival rate for advanced TNBC patients falls below 30%. In our TORCHLIGHT study, we combined chemotherapy with an immune checkpoint inhibitor, which resulted in significantly prolonged PFS in TNBC patients, along with other significant survival benefits. I am delighted to see the acceptance of the NDA for toripalimab in combination with chemotherapy for the treatment of advanced TNBC. I eagerly anticipate its approval as it will provide better treatment options for TNBC patients in China!”

“For a very long time, the treatment of advanced TNBC has been incredibly challenging, and TNBC has posed a constant threat to patients’ lives,” said Dr. Jianjun ZOU, the Global Research and Development President of Junshi Biosciences. “We at Junshi Biosciences have remained steadfast in our patient-centric approach and successfully collaborated with researchers on the TORCHLIGHT study, which has demonstrated significant improvements in PFS and OS. We plan to work closely with regulatory authorities to expedite the approval process and address the unmet needs of countless TNBC patients in China as soon as possible.”

About Toripalimab

Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system’s ability to attack and kill tumor cells.

More than forty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and Europe. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types, including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.

In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI^®). Currently, there are six approved indications for toripalimab in China:

1. unresectable or metastatic melanoma after failure of standard systemic therapy;
2. recurrent or metastatic nasopharyngeal carcinoma (“NPC”) after failure of at least two lines of prior systemic therapy;
3. locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;
4. in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;
5. in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma (“ESCC”);
6. in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).

The first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for the treatment of melanoma.

In the United States, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine/cisplatin for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (“FDA”). The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (SCLC).

In Europe, marketing authorization applications (MAA) were accepted by the European Medicines Agency (EMA) and the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) for 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic ESCC, in December 2022 and February 2023.

About Junshi Biosciences

Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for an anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.

In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. In 2021, JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 administered with bamlanivimab, was granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116 (deuremidevir hydrobromide), a novel oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, has been approved for marketing in China and Uzbekistan. The JS016 and VV116 programs are a part of the company’s continuous efforts towards innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has about 3,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc.). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

GlobeNewswire Distribution ID 8844506

ScyllaDB is fast becoming the go-to database for global media streaming leaders as well as India’s top gamechangers

BANGALORE, India and SUNNYVALE, Calif., May 22, 2023 (GLOBE NEWSWIRE) — ScyllaDB announced today that ZEE5 is now using its high-performance database for its rapidly growing streaming business. By moving from DynamoDB to ScyllaDB Cloud (a fully managed database-as-a-service solution compatible with both DynamoDB and Cassandra), ZEE5 is able to handle an increased volume of database traffic faster, and at significantly lower costs.

Zee Entertainment Enterprises Ltd. (ZEEL) is a leading media and entertainment company that operates over 80 channels. The company distributes content to nearly 1.3 billion viewers over 190 countries. ZEE5, the OTT arm of ZEEL, is currently using ScyllaDB to power its watch history functionality and is in the process of moving additional business-critical content streaming use cases to ScyllaDB. The team behind this move anticipates that database traffic could triple in the next year; this move proactively prepares their infrastructure to respond to this massive scale.

“Ensuring a cloud-agnostic infrastructure is a key focus for us as ZEE5 continues to expand,” stated Mr. Kishore A K, the Chief Technology Officer of ZEE5. He further emphasized the significance of the partnership, stating, “This collaboration will elevate the user experience of our rapidly growing streaming business. By harnessing the power of ScyllaDB’s high-performance database, we can effectively manage increased database traffic, delivering enhanced speed and efficiency, all while achieving notable cost savings. The architecture of ScyllaDB, combined with its compatibility with modern cloud resources, positions it as an optimal solution for our critical content streaming needs. Ultimately, this partnership adds significant value for our viewers.”

“ScyllaDB has a unique architecture which allows our NoSQL database to take full advantage of modern cloud resources,” added Dor Laor, Co-Founder and CEO of ScyllaDB. “That’s how ScyllaDB achieves this impressive efficiency and price-performance that makes use cases that require predictable low latency and high throughput a perfect match for us. The ScyllaDB team is excited about our partnership with Zee and our growing presence within the dynamic IT high-technology industry in India. Zee joins an impressive group of ScyllaDB customers in the region – for example, gamechangers such as ShareChat and OlaCabs.”

About ScyllaDB

ScyllaDB is the database for data-intensive apps that require high throughput and low latency. It enables teams to harness the ever-increasing computing power of modern infrastructures – eliminating barriers to scale as data grows. Unlike any other database, ScyllaDB is built with deep architectural advancements that enable exceptional end-user experiences at radically lower costs. Over 400 game-changing companies like Expedia, Discord, Crypto.com, Zillow, Starbucks, Comcast, and Samsung use ScyllaDB for their toughest database challenges. ScyllaDB is available as free open source software, a fully-supported enterprise product, and a fully managed service on multiple cloud providers. For more information: ScyllaDB.com

Media Contact:

Wayne Ariola

wayne.ariola@scylladb.com

GlobeNewswire Distribution ID 8844411